Results: Multiple SNPs in the RAD50-IL13 region on chromosome 5q31.1 were associated with asthma: rs2244012 in intron 2 of RAD50 (P 5 3.04E-07). The HLA-DR/DQ region on chromosome 6p21.3 was also associated with asthma: rs1063355 in the 39 untranslated region of HLA-DQB1 (P 5 9.55E-06). Imputation identified several significant SNPs in the T H 2 locus control region 39 of RAD50. Imputation also identified a more significant SNP, rs3998159 (P 5 Asthma is a complex disease that is caused by the interaction of genetic susceptibility with environmental influences. Genomewide linkage studies, candidate-gene association studies, and genome-wide association studies (GWASs) represent 3 major approaches to investigate the association between genetic variants and disease development.
Genome-wide linkage studies have consistently identified regions linked to asthma or asthma-related traits on chromosome 2q, 5q, 6p, 12q, and 13q. 1 The most highly replicated regions with obvious candidate genes are chromosome 5q31-33 (including IL5, IL13, IL4, CD14, and adrenergic b-2-receptor) and 6p21 (including lymphotoxin-a [or TNFB], TNF, major MHC-II, HLA-DQB1, and HLA-DRB1).
2 In addition, a recent metaanalysis of genome-wide linkage studies of asthma, bronchial hyperresponsiveness, positive allergen skin prick test, and total IgE identified overlapping regions for multiple phenotypes on chromosomes 5q and 6p as well as 3p and 7p. 3 Unfortunately, genome-wide linkage studies can only identify genes with relative strong effects in broad regions that include many genes. Positional cloning studies have identified 6 genes for asthma: a disintegrin and metalloprotease domain 33 on chromosome 20p13, 4 dipeptidyl-peptidase 10 on 2q14.1, 5 PHD finger protein 11 on 13q14.11, 6 neuropeptide S receptor 1 (or GPRA) on 7p14.3, 7 MHC-I, G (HLA-G) on 6p21.3, 8 and cytoplasmic FMR1 interacting protein 2 on 5q33.3. Candidate-gene association studies have identified more than 100 genes for asthma and asthma-related traits.
2,10,11 Although candidate-gene association studies have identified many genes, only a few have been replicated extensively. Thus, only 14 genes including genes on 5q and 6p (adrenergic b-2-receptor, IL-4 receptor, HLA-DRB1, IL13, CD14, TNF, membrane-spanning 4-domains, subfamily A, member 2 [or FCER1B], IL4, a disintegrin and metalloprotease domain 33, signal transducer and activator of transcription 6, IL4 induced, IL10, HLA-DQB1, glutathione S-transferase p 1, and lymphotoxin-a) have been replicated in more than 20 independent studies. 10 Even for highly replicated genes, replication might be a result of winner's bias and/or loose replication standard (gene as a unit and related phenotypes).
A GWAS is a hypothesis-free approach able to identify novel genes with mild/moderate effects and thus has become the best approach for studying association between genes and common disease phenotypes. To date, only 4 GWASs have been performed for asthma and asthma-related traits. 12 The first GWAS of childhood asthma identified ORM1-like 3 on chromosome 17q12. 13 The second GWAS of serum YKL-40 levels identified chitinase 3-like 1 on 1q32.
14 The third GWAS was for a related trait, total Outcomes and Treatment Regimens serum IgE levels, and the most significant single nucleotide polymorphisms (SNPs) are in the Fc fragment of IgE, highaffinity I, receptor for a polypeptide gene (FCER1A) on chromosome 1q23, and the second highest region observed was RAD50 on 5q31. 15 The fourth GWAS of childhood asthma indicated phosphodiesterase 4D, cyclic adenosine monophosphate-specific (phosphodiesterase E3 dunce homolog, Drosophila) (PDE4D) on chromosome 5q12. 16 In this study, we performed a GWAS of asthma in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) population of severe or difficult to treat asthmatics to search for novel genes and to confirm previously identified genes involved in asthma. The purpose of the TENOR study was to investigate the natural history of asthma in a large cohort of well characterized patients with severe or difficult to treat asthma; no treatment intervention was involved, and patients continued to be treated by their asthma specialists.
17-19

METHODS
Study subjects
The TENOR study was a multicenter observational and longitudinal cohort study of 4756 patients with asthma described as ''severe or difficult-to-treat'' by their physicians, sponsored by Genentech and Novartis. 17 Subjects were included if they had physician-characterized difficult-to-treat asthma and met additional criteria based on frequency of urgent care visits and/or the use of multiple controller medications. The clinical sites from the original TENOR study were contacted and invited to participate in this study. Sites that agreed were mailed Oragene DNA saliva collection kits (DNA Genotek, Inc, Ontario, Canada), labeled with the TENOR participant identification number. Sites then mailed the kits to participating individuals, who sent their collected samples to the Center for Human Genomics at Wake Forest University School of Medicine. This process was required to maintain anonymity between investigators at Wake Forest University and the study participants. Unfortunately, the TENOR study had ended (end of 2004) before this project started, so it was difficult to recontact participants. A total of 607 samples had sufficient DNA for successful SNP genotyping. Table I shows the demographic data for the TENOR cases and the 2 control populations. The TENOR patients with asthma who were genotyped were similar in characteristics to the larger TENOR cohort.
General population controls were obtained by using the Illumina iControlDB client (www.illumina.com) to download genotypes for 3294 white individuals with genotype data available from any of the 3 available HumanHap550 k products (v1, v3, and -2v3). As shown in Table I , only age and sex data are available. Additional control samples for asthma-related quantitative traits were obtained from a separate GWAS for asthma. These 363 phenotyped controls had no personal or family history of asthma and had normal pulmonary function including lack of bronchial hyperresponsiveness or bronchodilator reversibility. Testing also included measures of atopy including total serum IgE levels (Table I ). HapMap samples (N 5 262) to be used for genetic ancestry check were also downloaded from the iControlDB database (Illumina, Inc) after selecting the HumanHap300_v1 genotyping product.
DNA was isolated by using the protocol described by DNA Genotek, and SNP genotyping was performed by using the Illumina HumanCNV370 BeadChip. The samples were clustered by first applying Illumina's cluster definition, removing samples with call rates less than 0.90, and then reclustering using the samples themselves.
Statistical analysis
PLINK (version 1.06; http://pngu.mgh.harvard.edu/purcell/plink/) 20 was the main software used to perform statistical analysis unless otherwise stated.
Quality control (QC) was applied to cases and controls separately because they were genotyped by using slightly different Illumina products. Genetic ancestry of the TENOR cases was determined using the HapMap 300 k dataset as a reference. Fixed 3 groups clustering and pairwise population concordance of 1.0E-05 based on identity-by-state (IBS) were used to cross-validate ethnic group identity. Subjects were removed if they (1) were not of European white descent, (2) had low genotyping call rates (<95%), (3) were discrepant or ambiguous for genetic sex (heterozygous haploid genotype percentage 0.01 or X chromosome homorozygosity F 0.9), (4) failed the cryptic relatedness check (PI_HAT > 0.125), or (5) were detected as an outlier (>6 SD for the first or second principal component). After subjects meeting these criteria were deleted, SNPs were deleted if the call rates were low (95%) or were inconsistent with Hardy-Weinberg equilibrium (P < 10E-04). QC was then applied on the subjects and SNPs of merged case-control dataset as done separately. SNPs were also deleted if the minor allele frequency (MAF) was less than 0.05 in cases and controls or the Hardy-Weinberg equilibrium P value was less than .01 in controls only.
Asthma susceptibility was analyzed by comparing the non-Hispanic white TENOR cases to the general population Illumina controls. To reduce population stratification, 4 controls were matched with every 1 case based on pairwise IBS. Principal components were generated by using principal components analysis in EIGENSTRAT (version 3.0; http://genepath.med.harvard.edu/;reich/Software.htm). 21 Sex, age, and significant principal components were used as covariates in the logistic additive model. Genomic control (GC) was applied on P values to reduce population stratification further. 22 A linear model was analyzed in GWAS-identified candidate regions in 473 TENOR cases and 363 phenotyped controls for asthma-related quantitative traits (total serum IgE, % predicted FEV 1 , forced vital capacity [FVC] , and FEV 1 /FVC).
Haploview (http://www.broad.mit.edu/mpg/haploview/) was used to generate linkage disequilibrium plots. 23 Ninety-five percent CIs on D' were used to define blocks. 24 SNAP (version 2.0; http://www.broad.mit.edu/mpg/ snap/) was used to generate the association plots. 25 Imputation was performed based on HapMap II CEU genotype data 26 by using MACH (version 1.0; http://www.sph.umich.edu/csg/abecasis/MaCH/index.html). 27 Association of candidate SNPs with nearby gene expression data in lymphocytes was performed based on the GENEVAR dataset (http://www.sanger.ac.uk/humgen/ genevar/) 28 by using WGAViewer. 29 
RESULTS
A total of 607 TENOR cases were genotyped with the HumanCNV370 BeadChip. After removal of nonwhite samples (see this article's Fig E1 in the Online Repository at www.jacion line.org) and removal on the basis of the QC criteria, data from 474 patients with asthma were carried forward to analysis. Of the 3294 Illumina white controls downloaded from iControldb, 3,141 Illumina controls passed QC. After merging 474 TENOR cases with 3141 Illumina controls and evaluating the combined QC metrics, 473 cases and 3106 controls were retained. To reduce population stratification, 4 controls were matched with every 1 case on the basis of pairwise IBS; thus, 473 cases and 1892 Illumina controls were used for GWAS (see Table I The GWAS of asthma was performed on 292,443 SNPs of 473 TENOR cases and 1892 Illumina controls with sex, age, and significant principal components as covariates in the logistic additive model (Fig 1) . GC was applied to P values to reduce Table E1 ). The RAD50-IL13 region had the strongest evidence for association (Table II; Fig 2, A) with multiple SNPs in this region strongly associated with asthma susceptibility (rs2244012, rs6871536, and rs2897443 in RAD50 ranked highly as 1, 2, and 4, respectively, in this study). rs2244012 in intron 2 of RAD50 had an odds ratio of 1.64 (95% CI, 1.36-1.97; P 5 3.04E-07; GC-adjusted P 5 7.69E-07). Three SNPs in or near IL13 (rs2243204 [39 downstream], rs20541 [Arg130Gln], and rs1295686 [intron 3]) were also associated with asthma (P < .001), but in weak LD (0.2 < r 2 < 0.3) with SNPs in RAD50 (Fig 2, A and B) . rs2243300, which is ;5 kb upstream of IL4, was weakly associated with asthma (P 5 .0032). Six SNPs downstream of IL5 were not associated with asthma, although they were in weak LD with SNPs in RAD50 (Table II; Fig 2, A and  B) . Four LD blocks were identified based on 95% CI of D' (Fig  2, B) .
24 Blocks 1 and 2 were each composed of 3 SNPs downstream of IL5. Block 3 was composed of 4 SNPs in the intron of RAD50. Block 4 was composed of 2 SNPs in IL13.
Linear model analysis was performed with the 14 SNPs of the T H 2 cytokine locus in 473 TENOR cases and 363 phenotyped controls for asthma-related quantitative traits (total serum IgE, FEV 1 , FVC, and FEV 1 /FVC; Table II ). Multiple SNPs in each gene-RAD50, IL13, and IL4, but not IL5-showed significant association (P .05) with asthma-related quantitative traits.
The HLA-DR/DQ region (Table III; Fig 3, A) also showed consistent association with asthma. rs1063355 in the 39 untranslated region of HLA-DQB1 had an odds ratio of 0.68 (95% CI, 0.58-0.81; P 5 9.55E-06; GC-adjusted P 5 1.93E-05). Ten of the 46 SNPs in the HLA-DR/DQ region had P .001 (Table III; Fig 3, A) . Multiple SNPs in or near butyrophilin-like 2, HLA-DRA, HLA-DRB1, HLA-DQB1, and HLA-DQA2, were strongly associated with asthma (P < 10E-04). LD is complicated in this region when considering all 46 SNPs (data not shown). One LD block composed of 3 SNPs upstream of HLA-DQB1 was formed on the basis of the 95% CI of D' of these 10 SNPs (Fig 3, B) .
Linear model analysis was performed with the 10 SNPs of the HLA-DR/DQ region for asthma-related quantitative traits (Table  III) . A single SNP, rs1063355, on HLA-DQB1 showed significant association with asthma-related quantitative traits (P 5 .01, .001, .007, and .05 for total serum IgE, FEV 1 , FVC, and FEV 1 /FVC, respectively).
DISCUSSION
The highest associated SNP identified in this study was rs2244012 in intron 2 of RAD50 (P 5 3.04E-07). In addition, evidence was observed for association with multiple SNPs in the RAD50-IL13 region for asthma susceptibility and asthma related quantitative traits. The protein encoded by RAD50 is involved in DNA double-strand break repair, and its expression level is constitutively low in most tissues; thus, it has no known function directly related to asthma, although the MER11-RAD50-NBS1 complex has been shown to be involved in somatic hypermutation and gene conversion of immunoglobulin regions. 30 On the contrary, other genes (IL4, IL5, and IL13) in the T H 2 cytokines locus are better candidates on the basis of their biologic functions. Three SNPs in IL13 in this study were associated with asthma. IL13 is critical to the pathogenesis of allergen-induced asthma and thus one of the most highly studied and replicated genes in both genomewide linkage and candidate-gene association studies. rs20541 (Arg130Gln or IL1314257GA), in the coding region of IL13, was also analyzed in this study and has been shown to be associated with asthma 31 and total serum IgE levels. 32 rs1800925 (IL13-1111CT), in the promoter region of IL13, has been shown to be associated with asthma 33 and total serum IgE levels. 34 In a GWAS with total serum IgE levels, 4 SNPs in RAD50 (rs2706347, rs3798135, rs2040704, and rs7737470), have been identified (P < 10E-04). 15 These 4 SNPs in RAD50 were in strong LD with rs1800925 (0.7 < r 2 < 0.8) and in weak LD with rs20541 (0.2 < r 2 < 0.3) in IL13. 15 These results are consistent with the results of this study because many of the TENOR patients with asthma were recruited from allergists' offices and the population has increased IgE levels. 18 Because the actual functional SNPs cannot be determined purely by their P values, it is difficult to dissect the association data of RAD50 from IL13 in this study or other genetic studies because of the degree of LD present in this chromosomal region. In a transgenic mouse study, a T H 2 locus control region (LCR) was identified as the 25-kb fragment at the 39 end of Rad50. 35 An LCR is defined experimentally as regulating the expression of linked genes in a copy number-dependent and tissue-specific manner. The T H 2 LCR is involved in the chromatin configuration to reorganize promoters of IL4, IL5, and IL13 in proximity and coregulation of T H 2 cytokine expression. 36 Seven Rad50 DNase I-hypersensitive sites (RHS1-7) were identified, where RHS4-7 formed the core of the LCR. 37 LCR-C (RHS7) and LCR-B (RHS6) were possible T H 2 cytokine expression enhancers; LCR-A (RHS6) and LCR-O (RHS5) were likely insulators.
38 RHS7 is essential for T H 2 cytokine expression by showing T H 2 specific demethylation after allergen stimulation and intrachromosomal interactions between LCR and the promoters of T H 2 cytokines. 39 Furthermore, RHS6, Rad50 promoter (RHS2), and IL5 promoter interacted with IFN-g (Ifng) on a different chromosome, which suggests an interchromosomal regulation of the expression of T H 1/T H 2 cytokines. 40 Although all these experiments were done in mouse, the RAD50 sequence is highly conserved in the LCR between human being and mouse. With imputation, multiple significant SNPs were found in the LCR (see this article's Table E2 in the Online Repository at www.jacionline.org): rs3798135 (P 5 1.49E-06, in RHS5/ LCR-O), rs12653750 (P 5 1.49E-06, in RHS6/LCR-A), rs2040704 (P 5 1.33E-06, in RHS6/LCR-B), and rs2240032 (P 5 6.68E-06, in RHS7/LCR-C). The association of rs2244012 with the expression levels of IL13 in lymphocytes from white adults based on the GENEVAR dataset was not significant (P 5 0.176), but may be a result of small sample size.
Because both a previous GWAS for total serum IgE levels and our GWAS of asthma identified RAD50, it appears to be a new candidate gene for asthma. Although it is still possible the signal from RAD50 is purely a result of its LD with the promoter of IL13, RAD50 deserves to be carefully studied when considering T H 2 cytokine locus.
HLA-DR/DQ also showed consistent association with asthma-for example, rs1063355 in the 39 untranslated region of HLA-DQB1 (P 5 9.55E-06), rs2239804 in intron of HLA-DRA (P 5 2.80E-05), and rs2516049 59 upstream of HLA-DRB1 (P 5 2.62E-05). HLA-DR/DQ is part of the HLA class II region, which is one of the most gene/variant-dense regions in the human genome and is associated with many diseases. 41 HLA-DQB1 and HLA-DRB1 have been shown to be associated with asthma in multiple independent studies. [42] [43] [44] Genetic variants in the HLA-DR/ DQ region have also been shown to be highly associated with HLA-DR/DQ gene expression, indicating that the association of HLA-DR/DQ with disease might be a result of gene expression levels in addition to antigen recognition. 45, 46 The association of rs2516049 with asthma in our study and with the expression levels of HLA-DRB1 (P 5 1.25E-04) in lymphocytes from white adults based on GENEVAR dataset indicated that the variant might function through expression level changes (see this article's Fig E4 in the Online Repository at www.jacionline.org). 28, 29 Imputation identified a SNP with a more significant P value, rs3998159 (P 5 1.45E-06), between HLA-DQB1 and HLA-DQA2 (see this article's Table E3 in the Online Repository at www.jacionline.org). It is difficult to determine the functional genes/SNPs in the HLA-DR/DQ region in our study because of the complicated LD pattern in this region. The long-range LD and haplotype analysis based on the MHC Haplotype Project may solve the issue. 47 Using a GWAS approach, this study is the first to confirm the association of RAD50-IL13 and HLA-DR/DQ regions with asthma susceptibility, regions that have been identified by multiple candidate-gene association studies and 1 genome-wide association study on total serum IgE levels. Our results weakly replicated the findings of the other GWAS: ORM1-like 3 and gasdermin B (GSDML; rs7216389) with asthma (P 5 .057); FCER1A (rs2251746) with total serum IgE (P 5 .040); and chitinase 3-like 1 (rs880633) with FEV 1 (P 5 .003), FVC (P 5 .031), and FEV 1 /FVC (P 5 .040). rs1588265 (P 5 .507) and rs1544791 (P 5 .678) in PDE4D with asthma were not replicated. GWAS of total serum IgE by Weidinger et al 15 identified several SNPs in RAD50 (P < 10E-04). In our study, the most significant SNP in RAD50 for total serum IgE is rs6871536 (P 5 2.61E-03). The geometric mean of total serum IgE in the study by Weidinger et al 15 is 42.41 (95% CI, 39.56-45.47). In our study, the geometric mean of total serum IgE is higher, 48.94 (95% CI, 43.04-55.65). The difference in the total serum IgE distribution and the relatively small sample size in our study may lead to the difference of significant levels between these 2 studies.
The potential for false-negative results could not be avoided in this study because of the relatively small sample size (473 cases), which may also be the reason that although significance levels of 10 -7 (E-07) were observed, no SNP reached the Bonferroniadjusted multiple test criterion (P 5 .05/292,443 5 1.71E-07). However, evidence for multiple SNPs was observed in our results in this comprehensively phenotyped relatively homogeneous cohort of patients with difficult-to-treat asthma from the larger TENOR study. Our control datasets (general population and phenotyped controls) both have some limitations. They were both significantly younger (Table I) than TENOR cases, making our results a little conservative because some controls might become asthma cases in the future. Genotyping confirmation and fine-mapping of candidate regions were impossible because the Illumina controls were from a public database, but our approach compensated for this by using imputation. Population stratification was relatively strong between TENOR cases and Illumina 550k controls.
This GWAS confirmed the important role of T H 2 cytokine and antigen presentation genes in asthma at a genome-wide level. Furthermore, these findings will stimulate more comprehensive research (eg, resequencing, long-range LD, epistasis, epigenetics, copy number variant, and function) on these 2 regions because of their functional importance and structural complexity.
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Clinical implications: A GWAS of asthma identifies RAD50-IL13 and HLA-DR/DQ. These findings will stimulate more comprehensive research on these genes because of their structural complexity and functional importance in the pathogenesis of asthma. 
